DDR-Umbrella Study of DDR (DNA-Damage Response) Targeting Agents in Advanced Biliary Tract Cancer
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Camrelizumab (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 17 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 23 Nov 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 23 Nov 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Dec 2023.